Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18550549
Sumandea MP, et al. (2008) Tyrosine phosphorylation modifies protein kinase C delta-dependent phosphorylation of cardiac troponin I. J Biol Chem 283, 22680-9 18550549
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y311-p - PKCD (rat)
Modsite: TPETVGIyQGFEKKT SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y313‑p, PKCD iso2 (human): Y313‑p, PKCD (mouse): Y311‑p, PKCD iso2 (mouse): Y311‑p, PKCD (rat): Y311‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
PP1 H2O2 inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

Y332-p - PKCD (rat)
Modsite: IPDNNGTyGKIWEGS SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y334‑p, PKCD iso2 (human): Y365‑p, PKCD (mouse): Y332‑p, PKCD iso2 (mouse): Y358‑p, PKCD (rat): Y332‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
PP1 H2O2 inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

T505-p - PKCD (rat)
Modsite: FGENRAstFCGTPDy SwissProt Entrez-Gene
Orthologous residues
PKCD (human): T507‑p, PKCD iso2 (human): T538‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  rat
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

Y419-p - Src (rat)
Modsite: RLIEDNEyTARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
PP1 H2O2 inhibit treatment-induced increase

S23-p - TNNI3 (rat)
Modsite: PAPVRRRssANYRAY SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): S23‑p, TNNI3 (mouse): S23‑p, TNNI3 (rat): S23‑p, TNNI3 (rabbit): S22‑p, TNNI3 (dog): S23‑p, TNNI3 (cow): S24‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PRKD1 (human)
KINASE PKCD (rat)
KINASE PKACA (human)
KINASE PKCB iso2 (human)
KINASE PKCA (human)
Comments:  Lipid activated PKCD phosphorylates TNNI3 S22/23. Src tyrosin phosphorylates PKCD which can phosphorylate TNNI3 T144.

S24-p - TNNI3 (rat)
Modsite: APVRRRssANYRAYA SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): S24‑p, TNNI3 (mouse): S24‑p, TNNI3 (rat): S24‑p, TNNI3 (rabbit): S23‑p, TNNI3 (dog): S24‑p, TNNI3 (cow): S25‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKACA (human)
KINASE PKCD (rat)
KINASE PKCB iso2 (human)
KINASE PRKD1 (human)
KINASE PKCA (human)
Comments:  Lipid activated PKCD phosphorylates TNNI3 S22/23. Src tyrosin phosphorylates PKCD which can phosphorylate TNNI3 T144.

T144-p - TNNI3 (rat)
Modsite: RGKFkRPtLRRVRIs SwissProt Entrez-Gene
Orthologous residues
TNNI3 (human): T143‑p, TNNI3 (mouse): T144‑p, TNNI3 (rat): T144‑p, TNNI3 (rabbit): T143‑p, TNNI3 (dog): T144‑p, TNNI3 (cow): T145‑p